e-learning
resources
ERJ
2014
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis
Schupp Jonas, Becker Mike, Günther Jeannine, Müller-Quernheim Joachim, Riemekasten Gabriela, Prasse Antje
Source:
Eur Respir J 2014; 43: 1530-1532
Journal Issue:
May
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Schupp Jonas, Becker Mike, Günther Jeannine, Müller-Quernheim Joachim, Riemekasten Gabriela, Prasse Antje. Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis. Eur Respir J 2014; 43: 1530-1532
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Definition and history of sarcoidosis
Evidence of early abnormal airways’ inflammation in children with type 1 diabetes
Related content which might interest you:
Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis
Source: Eur Respir J 2011; 38: 1355-1360
Year: 2011
CCL18 as marker of disease progression in systemic sclerosis
Source: Annual Congress 2012 - Cystic lung diseases: lung granulomatosis
Year: 2012
Predictors of progression in systemic sclerosis patients with interstitial lung disease
Source: Eur Respir J, 55 (5) 1902026; 10.1183/13993003.02026-2019
Year: 2020
Serum interleukin 6 levels predict disease progression in scleroderma-associated interstitial lung disease
Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease
Year: 2010
Survival and prognostic factors in progressive systemic sclerosis with lung involvement
Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease
Year: 2009
MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis
Source: ERJ Open Res, 3 (1) 00074-2016; 10.1183/23120541.00074-2016
Year: 2017
Serum KL-6 as a marker of disease progression in SSc-ILD
Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside
Year: 2018
Plasma microfibrillar-associated protein 4 is not prognostic of emphysema progression but is associated with cardiovascular disease history and mortality in COPD patients
Source: ERJ Open Res, 5 (2) 00021-2019; 10.1183/23120541.00021-2019
Year: 2019
Increased CCL18 serum levels in patients with pulmonary fibrosis which reflect disease severity
Source: Eur Respir J 2005; 26: Suppl. 49, 21s
Year: 2005
IGFBP-2: a new pathway in systemic sclerosis associated interstitial lung disease
Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new?
Year: 2019
Circulating fibrocytes as prognostic biomarkers of autoimmune interstitial lung disease
Source: ERJ Open Res, 6 (4) 00481-2020; 10.1183/23120541.00481-2020
Year: 2020
Frequency and impact of interstitial lung disease on clinical state and mortality in systemic scleroderma
Source: Annual Congress 2012 - Diffuse parenchymal lung disease III
Year: 2012
BNP can be an all-cause mortality predictor in sarcoidosis
Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis
Year: 2013
Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD
Source: Eur Respir J 2016; 47:1365-1373
Year: 2016
Predicting progression of RA-ILD using anti-CCP
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
Serum KL-6 as a biomarker to assess response to azathioprine in connective tissue disease associated lung disease (CTD-ILD)
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
Predictors of mortality and risk prediction among patients with scleroderma related interstitial lung disease
Source: International Congress 2015 – IPF: clinical aspects II
Year: 2015
Interstitial lung disease with ANCA-associated vasculitis (AAV-ILD): Clinical features and survival compared to patients with ILD associated with systemic sclerosis and IPF
Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Year: 2020
Serum osteoprotegerin expression correlates with disease progression and severity in rodent models of pulmonary arterial hypertension
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis
Source: Eur Respir J 2009; 34: 1376-1382
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept